pembrolizumab monoclonal antibody drug. targets programmed cell death 1 (pd-1) and is used in the treatment of cancer (immune

antibody biological biosimilar biotech biotechnology blockade blocker cancer cell checkpoint death disease drug immune immunoglobulin immunology immunooncology immunotherapy infusion inhibitor injection inn lambrolizumab lung lymphocyte mab melanoma metastasis metastatic monoclonal nomenclature nsclc pd1 pembrolizumab peptide programmed protein receptor tcell